Claritas Healthcare — 2021 Investments
1 investments dated 2021 · listed companies and verified rows first · show all
Genomind provides pharmacogenetic testing and precision medicine software to help healthcare providers tailor medication prescriptions based on patients' genetic profiles, lifestyle, and environment.
Digital HealthHealthtechMedical DevicesKing of Prussia, US
Stephen Haller(Executive Officer)Gloria Nuss(Executive Officer)Beth E. Dozoretz(Executive Officer, Director)Thomas Hess(Executive Officer)Ronald I. Dozoretz(Executive Officer, Director, Promoter)Michael Koffler(Executive Officer, Director, Promoter)
Board seatJohn ChadwickTheresa Sexton· per SEC Form D · $21.1M raise · filed Apr 2021
Co-investorsClaritas Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.